Therapeutics News and Research

RSS

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

New research from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that it may be the quality of cancer stem cells rather than their quantity that leads to better survival in certain patients with oral cancer.

23 Jan 2014

ICR, Nuevolution and CRT partner to identify novel drug candidates for cancer treatment

The Institute of Cancer Research, London, Cancer Research Technology, London and Nuevolution A/S, Copenhagen have entered into a drug discovery collaboration to identify novel lead candidates for cancer treatment.

23 Jan 2014

Joint research program in SMA enters initial stage of clinical development

PTC Therapeutics, Inc., the SMA Foundation, and Roche, announced today that their joint research program in Spinal Muscular Atrophy has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers.

22 Jan 2014

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

The Damon Runyon Cancer Research Foundation announced that six scientists with novel approaches to fighting cancer have been named 2014 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

21 Jan 2014

Researchers identify molecular mechanism by which cocaine alters brain's reward circuits, causes addiction

Researchers from the Icahn School of Medicine at Mount Sinai have identified a new molecular mechanism by which cocaine alters the brain's reward circuits and causes addiction.

21 Jan 2014

RNA sequencing unlocks bipolar secrets

An RNA sequencing study of patients with bipolar disorder has shown altered expression of genes and transcripts, including those involved in neuroplasticity and circadian rhythms.

16 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Study shows direct link between metabolism in brain cells and ability to signal information

A new study by scientists at McGill University and the University of Zurich shows a direct link between metabolism in brain cells and their ability to signal information. The research may explain why the seizures of many epilepsy patients can be controlled by a specially formulated diet.

16 Jan 2014

Scientist receives € 2M Consolidator Grant for creation of new anti-tumour drugs

scar Fern-ndez-Capetillo's research group has developed compounds that only a few weeks ago were licensed by the Spanish National Cancer Research Centre (CNIO) to a pharmaceutical company for the creation of new anti-tumour drugs.

16 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Christopher Parsons, MD, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans, is the senior author of a paper that is the first to report that specialized fat (lipid) molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses.

15 Jan 2014

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”.

14 Jan 2014

Researchers reveal newest weapon to visualize shape and motion of RNA

Qi Zhang sees himself as a warrior. In his lab at the University of North Carolina at Chapel Hill, he wages war on genetic diseases such as cancer and heart disease on a battlefield measured with single atoms.

10 Jan 2014

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April.

9 Jan 2014

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

9 Jan 2014

Zymeworks, ImClone Systems partner to develop novel bi-specific antibody oncology therapeutics

Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.

9 Jan 2014

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Proteon Therapeutics, Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced that its lead product, PRT-201, has received orphan drug designation in the European Union for the prevention of arteriovenous access dysfunction in hemodialysis patients.

9 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

Therapeutics News and Research

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

ICR, Nuevolution and CRT partner to identify novel drug candidates for cancer treatment

Joint research program in SMA enters initial stage of clinical development

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

Researchers identify molecular mechanism by which cocaine alters brain's reward circuits, causes addiction

RNA sequencing unlocks bipolar secrets

Biothera enhances innate immune responses to Imprime PGG drug candidate

Study shows direct link between metabolism in brain cells and ability to signal information

Scientist receives € 2M Consolidator Grant for creation of new anti-tumour drugs

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Researchers reveal newest weapon to visualize shape and motion of RNA

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Zymeworks, ImClone Systems partner to develop novel bi-specific antibody oncology therapeutics

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News